These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9815924)

  • 1. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.
    Bauer JJ; Sesterhenn IA; Mostofi KF; McLeod DG; Srivastava S; Moul JW
    Clin Cancer Res; 1995 Nov; 1(11):1295-300. PubMed ID: 9815924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.
    Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Srivastava S; Moul JW
    J Urol; 1996 Oct; 156(4):1511-6. PubMed ID: 8808919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
    Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
    Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.
    Bettencourt MC; Bauer JJ; Sesterhenn IA; Mostofi FK; McLeod DG; Moul JW
    J Urol; 1996 Sep; 156(3):1064-8. PubMed ID: 8709308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low p27 expression predicts poor disease-free survival in patients with prostate cancer.
    Yang RM; Naitoh J; Murphy M; Wang HJ; Phillipson J; deKernion JB; Loda M; Reiter RE
    J Urol; 1998 Mar; 159(3):941-5. PubMed ID: 9474188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
    Theodorescu D; Broder SR; Boyd JC; Mills SE; Frierson HF
    J Urol; 1997 Jul; 158(1):131-7. PubMed ID: 9186339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caveolin-1 expression is a predictor of recurrence-free survival in pT2N0 prostate carcinoma diagnosed in Japanese patients.
    Satoh T; Yang G; Egawa S; Addai J; Frolov A; Kuwao S; Timme TL; Baba S; Thompson TC
    Cancer; 2003 Mar; 97(5):1225-33. PubMed ID: 12599229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy.
    Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Koutsilieris M
    Anticancer Res; 2005; 25(4):3123-33. PubMed ID: 16080576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting pathological stage of localized prostate cancer using volume weighted mean nuclear volume.
    Fujikawa K; Matsui Y; Kobayashi T; Miura K; Oka H; Fukuzawa S; Takeuchi H
    J Urol; 2000 Nov; 164(5):1587-90. PubMed ID: 11025710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kurahashi T; Miyake H; Hara I; Fujisawa M
    J Urol; 2007 Feb; 177(2):757-61. PubMed ID: 17222676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53.
    Stricker HJ; Jay JK; Linden MD; Tamboli P; Amin MB
    Urology; 1996 Mar; 47(3):366-9. PubMed ID: 8633403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
    Rigaud J; Tiguert R; Decobert M; Hovington H; Latulippe E; Laverdiere J; Larue H; Lacombe L; Fradet Y
    Prostate; 2004 Feb; 58(3):269-76. PubMed ID: 14743466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy.
    Cheng L; Sebo TJ; Cheville JC; Pisansky TM; Slezak J; Bergstralh EJ; Pacelli A; Neumann RM; Zincke H; Bostwick DG
    Cancer; 1999 Mar; 85(6):1293-9. PubMed ID: 10189134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker.
    Yang G; Truong LD; Wheeler TM; Thompson TC
    Cancer Res; 1999 Nov; 59(22):5719-23. PubMed ID: 10582690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.
    Vis AN; Noordzij MA; Fitoz K; Wildhagen MF; Schröder FH; van der Kwast TH
    J Urol; 2000 Dec; 164(6):2156-61. PubMed ID: 11061947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.